Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-25. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
=== Natural === Natural metallopeptides with antibiotic, antimicrobial and anticancer properties have been of particular interest to the scientific community (e.g. the divalent bacitracin, histatin and Fe/Cu-bleomycin). At the same time there is an increasing attention to the role of metalloppeptides in disease development. For example, metallochemical interactions in brain tissue can contribute to neurodegenerative conditions due to the naturally high concentration of metal ions in the brain. Hence the metallochemical reactions occurring outside the physiologically healthy concentrations, can contribute to the development of diseases such as Alzheimer's disease. The condition is related to the β-amyloid metallopeptides. Another example are infectious prion polypeptides and specific isoforms of prion protein which contribute to disease transmission and development.
== Overview and terms == In the context of organometallic catalysis, an in situ reaction involves the real-time measurement of a catalytic process using techniques such as mass spectrometry, NMR, infrared spectroscopy, and gas chromatography to help gain insight into functionality of the catalyst. Approximately 90% of industrial precursor chemicals are synthesized using catalysts. Understanding the catalytic mechanism and active site is crucial to creating catalysts with optimal efficiency and maximal product yield. In situ reactor cell designs typically are incapable of pressure and temperature consistency required for true catalytic reaction studies, making these cells insufficient. Several spectroscopic techniques require liquid helium temperatures, making them inappropriate for real-world studies of catalytic processes. Therefore, the operando reaction method must involve in situ spectroscopic measurement techniques, but under true catalytic kinetic conditions. Operando (Latin for working) spectroscopy refers to continuous spectra collection of a working catalyst, allowing for simultaneous evaluation of both structure and activity/selectivity of the catalyst.
Trails Through Daybreak follows Van Arkride, a mix of a detective and bounty hunter known as a Spriggan, and high schooler Agnes Claudel, who hires Van to search for eight artifacts that hold the key to solving an apocalyptic mystery. The arc is set in Calvard and is considered the start of the second half of the series. The first game, Trails Through Daybreak, was released in Japan for the PlayStation 4 in 2021. It features an action-based battle system as well as updates to the traditional turn-based system. An English version was released by NIS America in July 2024 in addition to a Nintendo Switch version. A sequel, Trails Through Daybreak II, was released in Japan for the PlayStation 4 and PlayStation 5 in September 2022 and for the Switch in July 2024. The English version released in February 2025. A third game, Trails Beyond the Horizon, was released in Japan in September 2024 and worldwide in January 2026. A sequel to Trails Beyond the Horizon is planned to end the Calvard arc.
Sources: en.wikipedia.org
In the first few days after the call for overseas service on 9 August, the result in many TF units was hesitant, with some units only recording around 50% volunteering, partly because men with families were reluctant to leave well-paid jobs especially while there was talk of a German invasion of the homeland, but the pace rapidly accelerated and, within a fortnight, 70 infantry battalions and many other units had collectively volunteered for France. initially TF units were either fed into regular brigades or used for secondary tasks, such as guarding lines of communication but, by the end of April 1915, six full Territorial divisions had been deployed into the fight. The (Regular) Expeditionary Force of six divisions had been rapidly sent to the Continent, where, facing overwhelming odds, they secured the left flank of the French Army. Of the 90,000 members of the original BEF deployed in August, four-fifths were dead or wounded by Christmas. So the arrival of the Territorials, first as reinforcements and then in whole divisions came at a critical juncture, while the New Army was still forming and training. Many of the Territorial units suffered immediate heavy casualties and on the night of 20 April 1915 Second Lieutenant Geoffrey Woolley of the Queen Victoria Rifles, secured the first of the 71 Victoria Crosses won by Territorials in the First World War.
== Clinical significance == Mutations of the ADH5 gene and ALDH2 gene cause AMED syndrome, an autosomal recessive digenic multisystem disorder characterized by global developmental delay with impaired intellectual development, short stature, growth impairment and early development of myelodysplastic syndrome and bone marrow failure. The syndrome was first described in 2020.
MNPs vaccination might be an alternative from direct injection. Able to deliver bigger molecules than transdermal patch, MNPs can also deliver bioactive molecules with different physical sizes. Meaning that inactive virus or pathogen can be introduced in the body without discomfort or skin irritation from conventional injection. Possibly it can also reduce the cost of storage that usually needs to be transported in a particular temperature and condition. Stated in cdc.gov website, Mark Prausnitz, co-developer of the microneedle, says "A major advantage of the microneedle patch would be the ease of delivery." The MNPs are small and thin compared to bottles of vial, making it possible to transport in massive quantities in a single trip. Medical waste such as syringes and dirty needles are also eliminated, reducing the possibility of pathogen transmission of blood-borne disease in rural areas. In a study, measles coated MNPs might be resistant to higher temperature compared to vial transport. Higher temperature resistance is a safe bet in low income countries, where there is no such luxury for refrigeration. Furthermore, the delivery of the vaccine is controlled by the MNPs. Less requiring highly trained medical workers in developing countries to apply the vaccine. However, the study in MNPs measles vaccine is still under development, but opening possibilities in the future for other types of vaccines
Sources: en.wikipedia.org
== See also == Reductive stress Glutathione synthetase deficiency Ophthalmic acid roGFP, a tool to measure the cellular glutathione redox potential Glutathione-ascorbate cycle Bacterial glutathione transferase Thioredoxin, a cysteine-containing small protein with very similar functions to reducing agents Glutaredoxin, an antioxidant protein that uses reduced glutathione as a cofactor and is reduced nonenzymatically by it Bacillithiol Mycothiol γ-L-Glutamyl-L-cysteine
=== Culture === In the past century since its initial discovery, culturing the bacteria in vitro has been difficult. Without the ability to grow and maintain the bacteria in a laboratory setting, discoveries regarding its metabolism and antimicrobial sensitivity were greatly impaired. However, successful long-term cultivation of T. pallidum in vitro was reported in 2017. This was achieved using Sf1Ep epithelial cells from rabbits, which were a necessary condition for the continued multiplication and survival of the system. The medium TpCM-2 was used, an alteration of more simple media which previously only yielded a few weeks of culture growth. This success was the result of switching out minimal essential medium (MEM) with CMRL 1066, a complex tissue culture medium. With development, new discoveries about T. pallidum's requirements for growth and gene expression may occur and in turn, yield research beneficial for the treatment and prevention of syphilis, outside of a host. However, continuous efforts to grow T. pallidum in axenic culture have been unsuccessful, indicating that it does not satisfy Koch's postulates. The challenge likely stems from the organism's strong adaptation to residing in mammalian tissue, resulting in a reduced genome and significant impairments in metabolic and biosynthetic functions. Optimal growth occurs at 33-35 °C, hence infection and lesion development occur on warmer skin areas, but not on colder ones such as the colder ear.
=== Combinatorial library synthesis === Robotics have applications with combinatorial chemistry which has great impact on the pharmaceutical industry. The use of robotics has allowed for the use of much smaller reagent quantities and mass expansion of chemical libraries. The "parallel synthesis" method can be improved upon with automation. The main disadvantage to "parallel-synthesis" is the amount of time it takes to develop a library, automation is typically applied to make this process more efficient. The main types of automation are classified by the type of solid-phase substrates, the methods for adding and removing reagents, and design of reaction chambers. Polymer resins may be used as a substrate for solid-phase. It is not a true combinatorial method in the sense that "split-mix" where a peptide compound is split into different groups and reacted with different compounds. This is then mixed back together split into more groups and each groups is reacted with a different compound. Instead the "parallel-synthesis" method does not mix, but reacts different groups of the same peptide with different compounds and allows for the identification of the individual compound on each solid support. A popular method implemented is the reaction block system due to its relative low cost and higher output of new compounds compared to other "parallel-synthesis" methods. Parallel-Synthesis was developed by Mario Geysen and his colleagues and is not a true type of combinatorial synthesis, but can be incorporated into a combinatorial synthesis.
== Later life and legacy == Ramachandran was devastated by the death of his wife Rajalakshmi in 1998 and his health gradually deteriorated. During the last few years of his life, he suffered a stroke and was affected by Parkinson's disease. Ramachandran died on 7 April 2001, aged 78, in Chennai. Each year, the Council of Scientific and Industrial Research (CSIR) awards the "G N Ramachandran Gold Medal for Excellence in Biological Sciences & Technology" in his memory for work in Biological Sciences & Technology.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.